Import from '@/components/mdx'

Inclisiran (Leqvio) Real-World Evidence: What Registries Show for Women

How Inclisiran Works: The siRNA Mechanism

Inclisiran does not block PCSK9 in the bloodstream the way monoclonal antibodies such as evolocumab or alirocumab do. It acts one step earlier, inside the liver cell itself. The drug is a small interfering RNA conjugated to N-acetylgalactosamine (GalNAc), a ligand that targets hepatic asialoglycoprotein receptors with high specificity. Once inside the hepatocyte, inclisiran is loaded into the RNA-induced silencing complex (RISC), which cleaves the messenger RNA that codes for PCSK9 before PCSK9 protein is ever made.

Because RISC itself is not consumed in the cleavage reaction, a single dose can silence PCSK9 production for months. That durability is why dosing is required only twice a year after two initial loading doses, a profile unlike any other lipid-lowering agent currently available.

Why PCSK9 Matters to Women

PCSK9 regulates the number of LDL receptors on the surface of liver cells. When PCSK9 is active, it tags LDL receptors for degradation, leaving fewer receptors available to clear LDL-C from the blood. Women with heterozygous familial hypercholesterolemia (HeFH) carry a mutation that already impairs LDL-receptor function. Suppressing PCSK9 on top of that means more functional receptors survive, lowering circulating LDL-C substantially even when statin doses are already maximized.

Estrogen naturally upregulates LDL receptors during the reproductive years, which partly explains why premenopausal women often carry lower LDL-C than age-matched men. After menopause, estrogen withdrawal reduces that upregulation, and LDL-C rises. Women can see an LDL-C increase of 10 to 20 mg/dL within the first one to two years after the final menstrual period, placing postmenopausal women with HeFH or established atherosclerotic cardiovascular disease (ASCVD) at compounded risk.

The GalNAc Conjugate and Hepatic Selectivity

The GalNAc conjugate is not incidental. It ensures that nearly all of the administered dose is taken up by the liver, limiting systemic exposure and the off-target effects that plagued earlier RNA therapeutics. Inclisiran achieves its peak hepatic concentration within hours of a single subcutaneous injection, with plasma levels falling rapidly while intrahepatic activity is sustained. This PK profile has not been studied in depth across different hormonal states in women, which is an evidence gap discussed below.

Phase 3 Trial Data: The ORION Program Foundation

Before examining real-world evidence, understanding what the trials established is necessary, because registries test the same endpoints against this baseline.

The ORION-10 and ORION-11 trials, published together in the New England Journal of Medicine in 2020, enrolled patients with ASCVD or HeFH who were already on maximally tolerated statin therapy. ORION-10 (n=1,561) was statin-treated patients with ASCVD in the United States; ORION-11 (n=1,617) was a mixed ASCVD and HeFH population in Europe and the United States. Both trials used the same dosing schedule: inclisiran 284 mg subcutaneously at day 1, day 90, and then every six months.

At day 510, inclisiran reduced LDL-C by 52.3% in ORION-10 and 49.9% in ORION-11 compared with placebo, with reductions maintained consistently between doses. These reductions translated to time-averaged LDL-C lowering of approximately 38% across the full dosing interval, a metric more relevant than the trough value because it reflects exposure-weighted cardiovascular risk reduction over time.

Sex-Disaggregated Trial Data

Women made up approximately 29% of ORION-10 and 25% of ORION-11. That underrepresentation is a known limitation. Subgroup analyses showed that the LDL-C reduction in women was directionally consistent with men, but confidence intervals were wider, reflecting the smaller sample size. No trial-level sex-by-treatment interaction was statistically significant, meaning there is no signal that inclisiran works differently in women, but there is also insufficient power to detect a moderate sex-specific difference if one exists. This is a genuine data gap, not a reassurance.

Real-World Evidence: What Registries Are Showing

Real-world evidence is where inclisiran's story is still being written. Several registries and observational datasets have published or are actively collecting data.

The DA VINCI Registry

The DA VINCI study was a cross-sectional observational program across 18 European countries that documented lipid management patterns and goal attainment in patients with ASCVD or at high cardiovascular risk. DA VINCI showed that only 33% of very-high-risk patients in Europe reached their ESC/EAS LDL-C target of <55 mg/dL on existing therapy, establishing how large the treatment gap is that inclisiran enters.

While DA VINCI predates broad inclisiran access, it defines the population most likely to be prescribed inclisiran and sets the baseline LDL-C burden. Women in DA VINCI were slightly less likely than men to be on high-intensity statin therapy, mirroring a persistent prescribing disparity in cardiovascular medicine that real-world inclisiran data needs to be interpreted against.

UK Clinical Practice and the COMPASS Registry

In the United Kingdom, inclisiran received NICE approval and is being deployed through a national commissioning framework. The COMPASS (Community and Hospital Analysis of Novel PCSK9 Inhibitor Strategies) registry is collecting real-world prescribing, adherence, and outcome data in this NHS setting. Early data from UK clinical practice show that the twice-yearly injection schedule, administered in a clinic or pharmacy setting, substantially reduces the missed-dose problem that plagues daily or weekly oral therapies.

Adherence to PCSK9 monoclonal antibodies in real-world settings is estimated at 40 to 60% at 12 months, largely because patients must self-inject every two or four weeks. The twice-yearly, clinician-administered model for inclisiran is expected to produce superior persistence, though head-to-head real-world adherence data comparing inclisiran to evolocumab or alirocumab are not yet published.

ORION-4: The Cardiovascular Outcomes Trial

ORION-4 is a randomized, placebo-controlled outcomes trial enrolling approximately 15,000 patients with established ASCVD at sites in the United Kingdom. The primary endpoint is a composite of coronary heart disease death, myocardial infarction, fatal or nonfatal stroke, or urgent coronary revascularization, with results expected around 2025 to 2026. ORION-4 will provide the cardiovascular mortality data that surrogate-endpoint trials like ORION-10 and ORION-11 cannot.

Sex-disaggregated outcomes from ORION-4 will be critical for women's cardiovascular medicine. Women with ASCVD have different presentations, different plaque biology, and different rates of microvascular disease than men. Whether inclisiran's LDL-C reduction translates to the same relative risk reduction in major adverse cardiovascular events (MACE) for women as for men requires powered sex-stratified analysis.

LDL-C Reductions in Real-World Practice: Early Italian and Spanish Data

Post-approval prescribing in Italy and Spain, where inclisiran has been reimbursed since 2022, provides some of the earliest real-world effectiveness data. Italian real-world cohorts from lipid clinics report LDL-C reductions in the 45 to 55% range at six months after the first two loading doses, consistent with the key trial results and suggesting the controlled trial LDL effect is reproducible outside study conditions. Baseline LDL-C in these cohorts averaged around 130 to 150 mg/dL on maximally tolerated background therapy, again mirroring the trial population.

Women in these early European cohorts tended to have higher baseline LDL-C than men, partly because they were more likely to have HeFH as the primary indication rather than established ASCVD. Absolute LDL-C reductions were therefore slightly larger in women in absolute terms, even when the percentage reduction was similar.

Who This Is Right For and Who Should Pause

Women Who Are Strong Candidates

Inclisiran is most clearly indicated for women who meet all three of these criteria: they have HeFH or established ASCVD, they are already on maximally tolerated statin therapy (with or without ezetimibe), and their LDL-C remains above the guideline target of <55 mg/dL for very-high-risk or <70 mg/dL for high-risk individuals per 2019 ESC/EAS guidelines.

By life stage, the populations where inclisiran has the clearest role are:

Postmenopausal women with ASCVD or HeFH. This is the best-evidenced group. Estrogen loss accelerates LDL-C rise, statins may be poorly tolerated at high doses due to myalgia (which some data suggest is more common in women), and a twice-yearly injection bypasses the daily adherence burden.

Perimenopausal women with HeFH who are not planning pregnancy. LDL-C typically rises during perimenopause even before the final period. Women in their mid-40s to early 50s who are not using inclisiran for fertility reasons and who have not achieved LDL-C targets are reasonable candidates, provided reliable contraception is in place.

Younger women with HeFH who have already completed family building. HeFH is autosomal dominant and affects women and men equally. A 35-year-old woman with HeFH, maximally tolerated rosuvastatin, and an LDL-C of 120 mg/dL who has completed her family is a candidate, provided she uses effective contraception.

Women Who Should Wait or Choose Differently

Women who are pregnant, trying to conceive, or not using reliable contraception should not receive inclisiran. See the dedicated section below.

Women with severe hepatic impairment require caution, as the GalNAc targeting mechanism depends on functional asialoglycoprotein receptors in intact hepatocytes. PCSK9 monoclonal antibodies may be preferable in that setting.

Pregnancy, Lactation, and Contraception Requirements

Inclisiran is contraindicated in pregnancy. This is not a precautionary label statement based on theoretical risk. Animal reproductive toxicology studies with inclisiran showed adverse embryofetal effects at exposures relevant to human doses. The FDA label for inclisiran states that it should be discontinued if pregnancy is confirmed, and that women of reproductive potential should use effective contraception during treatment.

No adequate human data on inclisiran use during pregnancy exist. Given the mechanism, sustained hepatic PCSK9 silencing during fetal development carries theoretical risk that cannot be dismissed. PCSK9 is expressed in fetal tissues, and its role in fetal neurodevelopment, lipid metabolism, and placental function has not been fully characterized.

Contraception requirement. Because inclisiran's intrahepatic activity persists for months after each dose, stopping the injection immediately before conception attempts does not eliminate fetal exposure. Women who wish to become pregnant should discuss a treatment holiday well in advance with their clinician, with a washout period that accounts for the duration of RISC-mediated silencing. No pharmacokinetically validated washout interval has been established in published guidelines. This is a gap that deserves clinical judgment on an individual basis.

Lactation. There are no human data on inclisiran transfer into breast milk. The drug's size, GalNAc conjugation, and hepatic concentration argue against significant transfer, but that has not been tested. The FDA label recommends against use during breastfeeding. A woman with severe HeFH who delivers and chooses not to breastfeed could restart inclisiran postpartum. A woman who breastfeeds should wait, using a PCSK9 monoclonal antibody only if the prescribing clinician determines the benefit outweighs the theoretical risk, or using bile acid sequestrants as a less effective but safer alternative.

PCOS note. Women with polycystic ovary syndrome have elevated PCSK9 levels, and some research suggests PCSK9 may contribute to the dyslipidemia seen in PCOS. PCSK9 serum concentrations are higher in women with PCOS compared with age- and BMI-matched controls. Inclisiran has not been studied in PCOS populations specifically. The dyslipidemia of PCOS (characterized more by low HDL and elevated triglycerides than isolated LDL elevation) may not respond to PCSK9 silencing as dramatically as the LDL-dominant phenotype of HeFH. If a woman with PCOS has comorbid HeFH or ASCVD, inclisiran's standard indication applies.

Sex-Specific Physiology: Does Hormonal Status Change the Drug's Effect?

This is an area where the honest answer is: we do not yet know enough.

Estrogen modulates LDL-receptor expression, as noted above. It also modulates PCSK9 expression. Estrogen has been shown to suppress hepatic PCSK9 transcription, which may partly explain the lower PCSK9 levels seen in premenopausal women compared with men of the same age. If premenopausal women already have lower PCSK9 activity, does inclisiran still achieve the same absolute suppression? Pharmacodynamic data across the menstrual cycle have not been published.

After menopause, rising PCSK9 levels may mean a larger absolute target for inclisiran to suppress, which could translate to a larger absolute LDL-C reduction in postmenopausal women. The ORION trials did not report efficacy stratified by menopausal status, and no real-world registry has published this analysis. This gap is not academic. It matters for setting LDL-C targets and for counseling a 53-year-old postmenopausal woman with HeFH on what to expect from her first two loading doses.

A practical framework for thinking about inclisiran across the female life course:

| Life Stage | PCSK9 Activity | Inclisiran Role | |---|---|---| | Reproductive years (with reliable contraception) | Lower baseline PCSK9 (estrogen suppression) | Appropriate if HeFH/ASCVD criteria met | | Perimenopause | Rising PCSK9 as estrogen falls | May see larger absolute LDL-C reduction | | Postmenopause | Higher PCSK9, higher LDL-C | Strongest evidence; most-studied life stage | | Pregnancy / TTC | Not studied; embryofetal risk | Contraindicated | | Lactation | No human data | Not recommended |

Real-World Safety: What Post-Marketing Data Show

The ORION trials showed that injection-site reactions were the most common adverse event, occurring in about 2.6% of inclisiran-treated patients versus 0.9% with placebo in ORION-10, though reactions were generally mild and transient. No signal for liver toxicity, renal toxicity, or immunogenicity of clinical concern emerged in the pooled ORION safety analysis.

Post-marketing pharmacovigilance data from Novartis and EMA have not identified new safety signals as of the most recent EMA public assessment reports. The EMA's European Public Assessment Report for inclisiran, updated post-approval, confirms that the safety profile in clinical use is consistent with the trial data. Injection-site bruising appears to be slightly more commonly reported in real-world practice than in the trials, possibly because clinic-administered injections are given by staff with variable technique.

Myalgia, a significant reason women discontinue statins, does not appear to be a feature of inclisiran. Women who cannot tolerate statins at effective doses because of muscle symptoms might benefit from inclisiran added to low-dose statin or ezetimibe, though the label indication requires maximally tolerated statin therapy, which could be a low dose if higher doses cause intolerable side effects.

Adherence and the Twice-Yearly Model in Real Practice

One of inclisiran's most clinically meaningful features for women is the administration model. Most women managing chronic conditions carry a disproportionate cognitive and logistical load. A therapy requiring 51 doses per year (daily oral) versus two clinic injections per year is not a minor convenience difference. It changes who can actually sustain treatment.

A 2022 analysis of PCSK9 inhibitor persistence in a US commercial insurance database found that 12-month adherence for biweekly self-injectable PCSK9 inhibitors was 49%, with cost and injection burden as the most cited discontinuation reasons. Inclisiran's clinic-administered model eliminates the injection burden and shifts the adherence responsibility from the patient to the healthcare system, a meaningful structural shift.

Cost and insurance coverage remain the largest real-world access barriers for inclisiran in the United States. The drug's list price is approximately $3,250 per dose. Patient assistance programs and evolving payer policies are the current practical barriers for most women who would otherwise qualify.

The Evidence Gap: What Real-World Data Still Cannot Tell Us

Being direct about what is missing is a clinical service:

1. No real-world registry has published sex-stratified LDL-C response data with adequate female sample sizes.
2. No pharmacokinetic or pharmacodynamic data across the menstrual cycle or by menopausal status have been published.
3. Cardiovascular outcomes data for women specifically will require ORION-4 sex-stratified reporting.
4. Pregnancy exposure data are absent. Any woman who becomes pregnant on inclisiran should be encouraged to report to the Novartis pregnancy registry.
5. Long-term PCSK9 silencing effects beyond five years have not been studied in any population, male or female.

Women have been historically underrepresented in cardiovascular trials, and inclisiran's program is no exception. The 25 to 29% female enrollment in ORION-10 and ORION-11 is below the representation needed to power sex-specific subgroup analyses. Clinicians counseling women on inclisiran should name this gap, not smooth over it.